Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleHot Topics

The Future of Radioligand Therapy: α, β, or Both?

Uwe Haberkorn, Frederik Giesel, Alfred Morgenstern and Clemens Kratochwil
Journal of Nuclear Medicine July 2017, 58 (7) 1017-1018; DOI: https://doi.org/10.2967/jnumed.117.190124
Uwe Haberkorn
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Giesel
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alfred Morgenstern
3European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Kratochwil
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Mechanisms enhancing efficacy of endoradiotherapy: cross-fire effect (CF, overlap of red circles) may compensate for target heterogeneity, RIBE (blue circle) leads to death of neighboring cells not directly exposed to irradiation, and abscopal effect (AbsE, green rectangle) induces responses also on remote lesions outside RIBE area and depends on induction of immune reactions.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Stratification of therapy according to bone marrow involvement. Maximum-intensity-projection PSMA ligand PET/CT in 2 patients. Patient lacking diffuse bone marrow infiltration (left) is candidate for treatment with 177Lu-PSMA ligand, whereas patient with infiltration of bone marrow (right) should be treated with 225Ac-PSMA ligand.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (7)
Journal of Nuclear Medicine
Vol. 58, Issue 7
July 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Future of Radioligand Therapy: α, β, or Both?
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The Future of Radioligand Therapy: α, β, or Both?
Uwe Haberkorn, Frederik Giesel, Alfred Morgenstern, Clemens Kratochwil
Journal of Nuclear Medicine Jul 2017, 58 (7) 1017-1018; DOI: 10.2967/jnumed.117.190124

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Future of Radioligand Therapy: α, β, or Both?
Uwe Haberkorn, Frederik Giesel, Alfred Morgenstern, Clemens Kratochwil
Journal of Nuclear Medicine Jul 2017, 58 (7) 1017-1018; DOI: 10.2967/jnumed.117.190124
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-{alpha} (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors
  • Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer
  • Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
  • mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
  • JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy
  • {alpha}-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies--Part 1
  • Google Scholar

More in this TOC Section

  • Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
  • RECIP 1.0: A Roadmap for Clinical Implementation
  • From Stabilization to Depletion: Molecular Imaging to Measure Therapeutic Response in ATTR-CA
Show more Hot Topics

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire